Short Interest in Humacyte, Inc. (NASDAQ:HUMA) Rises By 34.9%

Humacyte, Inc. (NASDAQ:HUMA) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 29,620,000 shares, an increase of 34.9% from the December 31st total of 21,960,000 shares. Based on an average daily volume of 4,700,000 shares, the short-interest ratio is presently 6.3 days. Approximately 28.4% of the company’s shares are sold short.

Humacyte Stock Up 1.0 %

Shares of Humacyte stock traded up $0.05 during trading on Thursday, reaching $4.61. 91,320 shares of the stock were exchanged, compared to its average volume of 2,520,663. The firm has a market cap of $579.59 million, a price-to-earnings ratio of -3.46 and a beta of 1.32. Humacyte has a 1 year low of $2.81 and a 1 year high of $9.97. The stock’s fifty day moving average is $4.52 and its 200 day moving average is $5.59.

Humacyte (NASDAQ:HUMA) last released its earnings results on Friday, November 8th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.08). During the same period last year, the company earned ($0.25) earnings per share. Equities analysts forecast that Humacyte will post -1.27 earnings per share for the current year.

Insider Activity at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 811,172 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the sale, the chief executive officer now owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. This trade represents a 25.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock worth $6,606,799 in the last 90 days. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. State Street Corp boosted its holdings in shares of Humacyte by 66.1% during the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after acquiring an additional 1,895,529 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Humacyte by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock worth $11,101,000 after acquiring an additional 179,120 shares during the last quarter. Millennium Management LLC increased its stake in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Humacyte by 10.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock valued at $3,924,000 after purchasing an additional 66,946 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after purchasing an additional 450,031 shares during the period. 44.71% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HUMA has been the topic of a number of research analyst reports. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Tuesday, January 21st. TD Cowen reaffirmed a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. BTIG Research reissued a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. Finally, Benchmark lifted their target price on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Humacyte has a consensus rating of “Buy” and an average price target of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.